Vicary Glenn W, Roman Jesse
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky.
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky; Division of Pulmonary, Critical Care, and Sleep Disorders Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky; Lousiville Veterans Affairs Medical Center, Louisville, Kentucky.
Am J Med Sci. 2016 Nov;352(5):507-516. doi: 10.1016/j.amjms.2016.08.014. Epub 2016 Aug 21.
Lung cancer is the leading cause of cancer death worldwide. Despite advances in its prevention and management, the prognosis of patients with lung cancer remains poor. Therefore, much attention is being given to factors that contribute to the development of this disease, the mechanisms that drive oncogenesis and tumor progression and the search for novel targets that could lead to the development of more effective treatments. One cellular pathway implicated in lung cancer development and progression is that of the mammalian target of rapamycin. Studies involving human tissues have linked lung cancer with abnormalities in this pathway. Furthermore, studies in vitro and in vivo using animal models of lung cancer reveal that targeting this pathway might represent an effective means of treating this disease. As a result, there is significant effort invested in the development of drugs targeting mammalian target of rapamycin and related pathways in the clinical setting.
肺癌是全球癌症死亡的主要原因。尽管在其预防和治疗方面取得了进展，但肺癌患者的预后仍然很差。因此，人们非常关注导致这种疾病发生的因素、驱动肿瘤发生和肿瘤进展的机制，以及寻找能够带来更有效治疗方法的新靶点。一条与肺癌发生和进展相关的细胞通路是雷帕霉素哺乳动物靶点通路。涉及人体组织的研究已将肺癌与该通路的异常联系起来。此外，使用肺癌动物模型进行的体外和体内研究表明，针对该通路可能是治疗这种疾病的有效手段。因此，在临床环境中，人们投入了大量精力来开发针对雷帕霉素哺乳动物靶点及相关通路的药物。
